Pathway Genomics Adds Leading Genetic Counselors to Advisory Board
News Apr 22, 2014
Pathway Genomics Corporation has announced that it has added industry-leading genetic counselors Jill Davies, M.S., CCGC, and Elissa Levin, M.S., CGC, to its genetic advisory board.
“Collaborating with expert genetic counselors is a critical part of Pathway’s dedication to providing clinical genetic information to patients and their physicians,” said Linda Wasserman, M.D., Ph.D., Pathway Genomics’ laboratory director and former director of the Clinical Cancer Genetics Care Unit at UC San Diego Moores Cancer Center. “Part of that dedication is to help patients learn about their genetic results through a genetic counselor.”
With more than 10 years as a genetic counselor, Jill Davies, M.S., CCGC, is the current director of genetics and genomics at Medcan Clinic, where she has developed a leading-edge genetics program with a range of services. Her special interest is in the role of genetics in primary care and preventive medicine, focusing on bringing the most advanced genetics knowledge to individuals to help them optimize health and manage risk for disease.
As the co-investigator on the Personal Genome Project Canada (PGPC), in 2012 she became the first Canadian to have her whole genome sequenced as part of this project. Davies is an active member of the Ontario Personalized Medicine Network, the National Society of Genetic Counselors and is a Canadian board-certified genetic counselor.
Elissa Levin, M.S., CGC, is the head of Genomics and Integrative Health Innovations and assistant professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai. Previously she was at Life Technologies, where she developed and led the clinical support services department, providing clinical genomics expertise to the global organization.
Levin began her career working in academic medical centers where she provided clinical genetic counseling for the Division of General and Metabolic Genetics at the University of California San Francisco and coordinated a multicenter, NIH-funded trial on the genetic basis of congenital heart disease at the Children's Hospital of Philadelphia.
Pathway Genomics’ advisory board consists of leaders in various fields including genetic counseling, oncology, pharmacogenomics, endocrinology, bioinformatics, biostatistics, behavioral genetics, nutrigenomics, and human epigenetics.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.